| Dr Paul F Poulin, MD | |
|
62 Brown St, Suite #401, Haverhill, MA 01830-6778 | |
| (978) 521-8590 | |
| (978) 521-8732 |
| Full Name | Dr Paul F Poulin |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 62 Brown St, Haverhill, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598759367 | NPI | - | NPPES |
| 110064751A | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 9050 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul F Poulin, MD 3 Electronics Ave, Ste 201, Danvers, MA 01923-1099 Ph: (978) 750-0300 | Dr Paul F Poulin, MD 62 Brown St, Suite #401, Haverhill, MA 01830-6778 Ph: (978) 521-8590 |
News Archive
The Howard Hughes Medical Institute (HHMI) today committed four years' worth of funding for an innovative biomedical training program between Rice University and the University of Texas M.D. Anderson Cancer Center.
Researchers using functional MRI (fMRI) have determined that the circuitry in the area of the brain responsible for suppressing memory is dysfunctional in patients suffering from stress-related psychiatric disorders.
While studying the mechanics of blood clots, researchers at the University of Oklahoma Health Sciences Center discovered a new enzyme that not only affects the blood, but seems to play a primary role in how cancer tumors expand and spread throughout the body.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
› Verified 6 days ago
Margaret Mary Hunt, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 145 Ward Hill Ave, Haverhill, MA 01835 Phone: 978-372-8000 | |
Dr. William Rogers Obrien Dibrielle, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Parkway, Haverhill, MA 01830 Phone: 978-521-3250 Fax: 978-469-5646 | |
Francis P. Macmillan, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1 Parkway, Haverhill, MA 01830 Phone: 978-521-3235 Fax: 978-521-3236 | |
Sunny Srivastava, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Parkway, Haverhill, MA 01830 Phone: 978-521-3288 Fax: 978-469-5644 | |
Beverly A. Brennan, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 600 Primrose St, Haverhill, MA 01830 Phone: 978-469-7100 Fax: 978-469-7199 | |
Dr. Jason M Hemming, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Park Way, Haverhill, MA 01830 Phone: 978-521-3235 Fax: 978-521-3236 | |
Dr. David A Byrne, M.D Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 62 Brown Street, Suite 200, Haverhill, MA 01830 Phone: 978-521-8377 Fax: 978-521-3689 |